IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX: COR) hosted a conference call on October 26, 2006 to discuss the lifting of the U.S. Food and Drug Administration’s clinical hold on Cortex’s lead product candidate, AMPAKINE® CX717, and to review the steps Cortex is taking to advance the development of CX717. A telephonic replay of the conference call will be available for 45 days after the call by dialing 1-877-660-6853 (domestic) or 1-201-612-7415 (international) and entering account number 286# and conference ID number 218465# when prompted.
